UK reg­u­la­tors cau­tion against switch­ing be­tween com­mon AD­HD meds

UK reg­u­la­tors have a mes­sage for AD­HD pa­tients and their providers: Take cau­tion when switch­ing be­tween long-act­ing forms of com­mon meds such as No­var­tis’ block­buster …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER